158 related articles for article (PubMed ID: 31430345)
1. An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer.
Pujol JL; Coffy A; Camerini A; Kotsakis A; Mencoboni M; Gusella M; Pasini F; Pezzuto A; Banna GL; Bilir C; Samantas E; Barlesi F; Roch B; Guillou A; Daurès JP
PLoS One; 2019; 14(8):e0220988. PubMed ID: 31430345
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and toxicity of metronomic oral vinorelbine monotherapy in patients with non-small cell lung cancer: a meta-analysis.
Xu K; Liu T; Zhang J; Zhou Y; Yang F; Ren T
Int J Clin Oncol; 2020 Sep; 25(9):1624-1634. PubMed ID: 32472208
[TBL] [Abstract][Full Text] [Related]
3. Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis.
Camerini A; Banna GL; Cinieri S; Pezzuto A; Mencoboni M; Rosetti F; Figueiredo A; Rizzo P; Ricci A; Langenhoven L; Santo A; Addeo A; Amoroso D; Barata F
Clin Transl Oncol; 2019 Jun; 21(6):790-795. PubMed ID: 30448956
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms.
Gusella M; Pasini F; Caruso D; Barile C; Modena Y; Fraccon AP; Bertolaso L; Menon D; Crepaldi G; Bononi A; Spezzano R; Telatin GA; Corona G; Padrini R
Cancer Chemother Pharmacol; 2019 Mar; 83(3):493-500. PubMed ID: 30542768
[TBL] [Abstract][Full Text] [Related]
5. Metronomic Oral Vinorelbine: An Alternative Schedule in Elderly and Patients PS2 With Local/Advanced and Metastatic NSCLC Not Oncogene-addicted.
Rossi D; Lippe P; Rocchi MBL; Sarti D; Catalano V; Graziano F; Giordani P; Baldelli A; Fedeli SL; Imperatori L; Laici G; Cappelletti C; Tamburrano T; Bracci R; Alessandroni P
In Vivo; 2020; 34(5):2687-2691. PubMed ID: 32871800
[TBL] [Abstract][Full Text] [Related]
6. Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC.
Mencoboni M; Filiberti RA; Taveggia P; Del Corso L; Del Conte A; Covesnon MG; Puccetti C; Donati S; Auriati L; Amoroso D; Camerini A
Anticancer Res; 2017 Jun; 37(6):3189-3194. PubMed ID: 28551663
[TBL] [Abstract][Full Text] [Related]
7. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.
Briasoulis E; Aravantinos G; Kouvatseas G; Pappas P; Biziota E; Sainis I; Makatsoris T; Varthalitis I; Xanthakis I; Vassias A; Klouvas G; Boukovinas I; Fountzilas G; Syrigos KN; Kalofonos H; Samantas E
BMC Cancer; 2013 May; 13():263. PubMed ID: 23718900
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group.
Kontopodis E; Hatzidaki D; Varthalitis I; Kentepozidis N; Giassas S; Pantazopoulos N; Vardakis N; Rovithi M; Georgoulias V; Agelaki S
J Chemother; 2013 Feb; 25(1):49-55. PubMed ID: 23433445
[TBL] [Abstract][Full Text] [Related]
9. Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer.
D'Ascanio M; Pezzuto A; Fiorentino C; Sposato B; Bruno P; Grieco A; Mancini R; Ricci A
Biomed Res Int; 2018; 2018():6278403. PubMed ID: 30225260
[TBL] [Abstract][Full Text] [Related]
10. Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy.
Banna GL; Camerini A; Bronte G; Anile G; Addeo A; Rundo F; Zanghì G; Lal R; Libra M
Anticancer Res; 2018 Jun; 38(6):3689-3697. PubMed ID: 29848729
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status.
Camerini A; Valsuani C; Mazzoni F; Siclari O; Puccetti C; Donati S; Rondini M; Tartarelli G; Puccinelli P; Di Costanzo F; Amoroso D
Ann Oncol; 2010 Jun; 21(6):1290-1295. PubMed ID: 19914959
[TBL] [Abstract][Full Text] [Related]
12. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial).
Camerini A; Puccetti C; Donati S; Valsuani C; Petrella MC; Tartarelli G; Puccinelli P; Amoroso D
BMC Cancer; 2015 May; 15():359. PubMed ID: 25943747
[TBL] [Abstract][Full Text] [Related]
13. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.
Platania M; Pasini F; Porcu L; Boeri M; Verderame F; Modena Y; Del Conte A; Nichetti F; Garassino MC; Martinetti A; Sottotetti E; Cavanna L; Vattemi E; Pozzessere D; Bertolini A; Irtelli L; Verri C; Sozzi G; Proto C; Pastorino U; Torri V; Fraccon AP; Spinnato F; Signorelli D; Lo Russo G; Tuzi A; Gallucci R; Cinieri S; Mencoboni M; Antonelli P; Giacomelli L; de Braud F
Lung Cancer; 2019 Jun; 132():17-23. PubMed ID: 31097088
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
[TBL] [Abstract][Full Text] [Related]
15. Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity.
Kanard A; Jatoi A; Castillo R; Geyer S; Schulz TK; Fitch TR; Rowland KM; Nair S; Krook JE; Kugler JW
Lung Cancer; 2004 Mar; 43(3):345-53. PubMed ID: 15165094
[TBL] [Abstract][Full Text] [Related]
16. Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients.
Barlesi F; Imbs DC; Tomasini P; Greillier L; Galloux M; Testot-Ferry A; Garcia M; Elharrar X; Pelletier A; André N; Mascaux C; Lacarelle B; Cheikh RE; Serre R; Ciccolini J; Barbolosi D
Oncotarget; 2017 Jul; 8(29):47161-47166. PubMed ID: 28525370
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
Clark JI; Kancharla K; Qamar R; Fisher S; Hantel A; Panganiban J; Millbrandt L; Albain KS
Lung Cancer; 2001 Nov; 34(2):271-7. PubMed ID: 11679186
[TBL] [Abstract][Full Text] [Related]
18. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
Bartsch V
Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and Toxicity of Metronomic Oral Vinorelbinen in Advanced Non-small Cell Lung Cancer after Failure to Multiple-lines Treatments].
Yao S; Gu Y; Zhang Y
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):737-740. PubMed ID: 29167002
[TBL] [Abstract][Full Text] [Related]
20. Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world.
Pasini F; Barile C; Caruso D; Modena Y; Fraccon AP; Bertolaso L; Menon D; La Russa F; Crepaldi G; Bononi A; Spezzano R; Padrini R; Corona G; Gusella M
Invest New Drugs; 2018 Oct; 36(5):927-932. PubMed ID: 29956056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]